BACKGROUND AND METHODS. The use of oral anticoagulation in the long-term treatment of survivors of acute myocardial infarction has been highly controversial. We therefore randomly assigned 1214 patients who had recovered from acute myocardial infarction (mean interval from the onset of symptoms to randomization, 27 days) to treatment with warfarin (607 patients) or placebo (607 patients) for an average of 37 months (range, 24 to 63). RESULTS. At the end of the treatment period, there had been 123 deaths in the placebo group and 94 in the warfarin group--a reduction in risk of 24 percent (95 percent confidence interval, 4 to 44 percent; P = 0.027). A total of 124 patients in the placebo group had reinfarctions, as compared with 82 in the warfarin group--a reduction of 34 percent (95 percent confidence interval, 19 to 54 percent; P = 0.0007). Furthermore, we observed a reduction of 55 percent (95 percent confidence interval, 30 to 77 percent) in the number of total cerebrovascular accidents in the warfarin group as compared with the placebo group (44 vs. 20; P = 0.0015). Serious bleeding was noted in 0.6 percent of the warfarin-treated patients per year. CONCLUSIONS. Long-term therapy with warfarin has an important beneficial effect after myocardial infarction and can be recommended in the treatment of patients who survive the acute phase.
Source Information
Department of Medicine, Red Cross Clinic, Oslo, Norway.
This article has been cited by other articles:
Holmes, D. R. Jr, Kereiakes, D. J., Kleiman, N. S., Moliterno, D. J., Patti, G., Grines, C. L.
(2009). Combining Antiplatelet and Anticoagulant Therapies.. J Am Coll Cardiol
54: 95-109
[Abstract][Full Text]
Authors/Task Force Members, , Van de Werf, F., Bax, J., Betriu, A., Blomstrom-Lundqvist, C., Crea, F., Falk, V., Filippatos, G., Fox, K., Huber, K., Kastrati, A., Rosengren, A., Steg, P. G., Tubaro, M., Verheugt, F., Weidinger, F., Weis, M., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Document Reviewers, , Silber, S., Aguirre, F. V., Al-Attar, N., Alegria, E., Andreotti, F., Benzer, W., Breithardt, O., Danchin, N., Mario, C. D., Dudek, D., Gulba, D., Halvorsen, S., Kaufmann, P., Kornowski, R., Lip, G. Y. H., Rutten, F.
(2008). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:. Eur Heart J
29: 2909-2945
[Full Text]
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., Palareti, G.
(2008). Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 160S-198S
[Abstract][Full Text]
Schulman, S., Beyth, R. J., Kearon, C., Levine, M. N.
(2008). Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 257S-298S
[Abstract][Full Text]
Singer, D. E., Albers, G. W., Dalen, J. E., Fang, M. C., Go, A. S., Halperin, J. L., Lip, G. Y. H., Manning, W. J.
(2008). Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 546S-592S
[Abstract][Full Text]
Becker, R. C., Meade, T. W., Berger, P. B., Ezekowitz, M., O'Connor, C. M., Vorchheimer, D. A., Guyatt, G. H., Mark, D. B., Harrington, R. A.
(2008). The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 776S-814S
[Abstract][Full Text]
Levi, M., Hovingh, G. K., Cannegieter, S. C., Vermeulen, M., Buller, H. R., Rosendaal, F. R.
(2008). Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood
111: 4471-4476
[Abstract][Full Text]
Friberg, L., Hammar, N., Pettersson, H., Rosenqvist, M.
(2007). Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J
28: 2346-2353
[Abstract][Full Text]
Lane, J. R., Ben-Shachar, G.
(2007). Myocardial Infarction in Healthy Adolescents. Pediatrics
120: e938-e943
[Abstract][Full Text]
Christersson, C., Oldgren, J., Bylock, A., Siegbahn, A., Wallentin, L.
(2007). Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM trial. Eur Heart J
28: 692-698
[Abstract][Full Text]
Nair, A., Sealove, B., Halperin, J. L., Webber, G., Fuster, V.
(2006). Anticoagulation in patients with heart failure: who, when, and why?. Eur Heart J Suppl
8: E32-E38
[Abstract][Full Text]
Husted, S.E., Ziegler, B.K., Kher, A.
(2006). Long-term anticoagulant therapy in patients with coronary artery disease. Eur Heart J
27: 913-919
[Abstract][Full Text]
Min, K. A., Zhu, X., Oh, J. M., Shin, W. G.
(2006). Effect of oxolamine on anticoagulant effect of warfarin. Am J Health Syst Pharm
63: 153-156
[Full Text]
Ioannidis, J. P. A.
(2005). Contradicted and Initially Stronger Effects in Highly Cited Clinical Research. JAMA
294: 218-228
[Abstract][Full Text]
Aronow, W. S.
(2004). Management of the Elderly Person After Myocardial Infarction. Journals of Gerontology Series A: Biological Sciences and Medical Sciences
59: 1173-1185
[Abstract][Full Text]
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., Hylek, E.
(2004). The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
126: 204S-233S
[Abstract][Full Text]
Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., Schulman, S.
(2004). Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
126: 287S-310S
[Abstract][Full Text]
Singer, D. E., Albers, G. W., Dalen, J. E., Go, A. S., Halperin, J. L., Manning, W. J.
(2004). Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
126: 429S-456S
[Abstract][Full Text]
Albers, G. W., Amarenco, P., Easton, J. D., Sacco, R. L., Teal, P.
(2004). Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
126: 483S-512S
[Abstract][Full Text]
Earl, M. A., Mauro, V. F.
(2004). The Clinical Impact of Administering Warfarin to Post-Myocardial Infarction Patients. Journal of Pharmacy Practice
17: 266-269
[Abstract]
Shikata, E., Ieiri, I., Ishiguro, S., Aono, H., Inoue, K., Koide, T., Ohgi, S., Otsubo, K.
(2004). Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and {gamma}-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood
103: 2630-2635
[Abstract][Full Text]
Herlitz, J., Holm, J., Peterson, M., Karlson, B. W, Haglid Evander, M., Erhardt, L., for the LoWASA study group,
(2004). Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction: the LoWASA Study. Eur Heart J
25: 232-239
[Abstract][Full Text]
Zibaeenezhad, M.J., Mowla, A., Sorbi, M.H.
(2004). Warfarin and Aspirin Versus Aspirin Alone in Patients with Acute Myocardial Infarction: A Pilot Study. ANGIOLOGY
55: 17-20
[Abstract]
Jeddy, A. S, Gleason, B. L
(2003). Aspirin and Warfarin Versus Aspirin Monotherapy After Myocardial Infarction. The Annals of Pharmacotherapy
37: 1502-1505
[Abstract][Full Text]
Hirsh, J., Fuster, V., Ansell, J., Halperin, J. L.
(2003). American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol
41: 1633-1652
[Full Text]
Hirsh, J., Fuster, V., Ansell, J., Halperin, J. L.
(2003). American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation
107: 1692-1711
[Full Text]
Anand, S. S., Yusuf, S.
(2003). Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol
41: 62S-69S
[Abstract][Full Text]
The Task Force on the Management of Acute Myocardi, , Van de Werf, F., Ardissino, D., Betriu, A., Cokkinos, D. V., Falk, E., Fox, K. A.A., Julian, D., Lengyel, M., Neumann, F.-J., Ruzyllo, W., Thygesen, C., Underwood, S. R., Vahanian, A., Verheugt, F. W.A., Wijns, W.
(2003). Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J
24: 28-66
[Full Text]
Algra, A., De Schryver, E.L.L.M., van Gijn, J., Kappelle, L.J., Koudstaal, P.J.
(2003). Oral Anticoagulants Versus Antiplatelet Therapy for Preventing Further Vascular Events After Transient Ischemic Attack or Minor Stroke of Presumed Arterial Origin. Stroke
34: 234-235
[Full Text]
Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., Arnesen, H.
(2002). Warfarin, Aspirin, or Both after Myocardial Infarction. NEJM
347: 969-974
[Abstract][Full Text]
Becker, R. C.
(2002). Antithrombotic Therapy after Myocardial Infarction. NEJM
347: 1019-1022
[Full Text]
Ambrose, J. A., Martinez, E. E.
(2002). A New Paradigm for Plaque Stabilization. Circulation
105: 2000-2004
[Abstract][Full Text]
Brouwer, M. A., Verheugt, F. W.A.
(2002). Oral Anticoagulation for Acute Coronary Syndromes. Circulation
105: 1270-1274
[Full Text]
Leebeek, F.W.G., Boersma, E., Cannon, C.P., van de Werf, F.J.J., Simoons, M.L.
(2002). Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable. Eur Heart J
23: 444-457
[Full Text]
Torn, MD;, M., Algra, MD;, A., Rosendaal, MD, F.R.
(2001). Oral anticoagulation for cerebral ischemia of arterial origin: High initial bleeding risk. Neurology
57: 1993-1999
[Abstract][Full Text]
Smith, S. C. Jr, Blair, S. N., Bonow, R. O., Brass, L. M., Cerqueira, M. D., Dracup, K., Fuster, V., Gotto, A., Grundy, S. M., Miller, N. H., Jacobs, A., Jones, D., Krauss, R. M., Mosca, L., Ockene, I., Pasternak, R. C., Pearson, T., Pfeffer, M. A., Starke, R. D., Taubert, K. A.
(2001). AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 Update: A Statement for Healthcare Professionals From the American Heart Association and the American College of Cardiology. Circulation
104: 1577-1579
[Full Text]
Priori, S.G., Aliot, E., Blomstrom-Lundqvist, C., Bossaert, L., Breithardt, G., Brugada, P., Camm, A.J., Cappato, R., Cobbe, S.M., Di Mario, C., Maron, B.J., McKenna, W.J., Pedersen, A.K., Ravens, U., Schwartz, P.J., Trusz-Gluza, M., Vardas, P., Wellens, H.J.J., Zipes, D.P.
(2001). Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J
22: 1374-1450
McGovern, P. G., Jacobs, D. R. Jr, Shahar, E., Arnett, D. K., Folsom, A. R., Blackburn, H., Luepker, R. V.
(2001). Trends in Acute Coronary Heart Disease Mortality, Morbidity, and Medical Care From 1985 Through 1997 : The Minnesota Heart Survey. Circulation
104: 19-24
[Abstract][Full Text]
Isnard, R., Komajda, M.
(2001). Thromboembolism in heart failure, old ideas and new challenges. Eur J Heart Fail
3: 265-269
[Abstract][Full Text]
Manca, G., Parenti, G., Bellina, R., Boni, G., Grosso, M., Bernini, W., Palombo, C., Paterni, M., Pelosi, G., Lanza, M., Mazzuca, N., Bianchi, R., De Caterina, R.
(2001). 111In Platelet Scintigraphy for the Noninvasive Detection of Carotid Plaque Thrombosis. Stroke
32: 719-727
[Abstract][Full Text]
Levine, M. N., Raskob, G., Landefeld, S., Kearon, C.
(2001). Hemorrhagic Complications of Anticoagulant Treatment. Chest
119
: 108S-121S
[Full Text]
Cairns, J. A., Theroux, P., Lewis, H. D. Jr., Ezekowitz, M., Meade, T. W.
(2001). Antithrombotic Agents in Coronary Artery Disease. Chest
119
: 228S-252S
[Full Text]
Albers, G. W., Amarenco, P., Easton, J. D., Sacco, R. L., Teal, P.
(2001). Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. Chest
119
: 300S-320S
[Full Text]
Kajubi, S. K.
(2000). Additional Monitoring Tools to Improve the Quality of Anticoagulation Management. Arch Intern Med
160: 3006-3006
[Full Text]
Altman, R., Rouvier, J., Scazziota, A.
(2000). State-of-the-Art Review : Secondary Prevention of Myocardial Infarction: Beneficial Effect of Combining Oral Anticoagulant Plus Aspirin: Therapy Based on Evidence. CLIN APPL THROMB HEMOST
6: 126-134
Witte, K., Thackray, S., Banerjee, T., Clark, A. L., Cleland, J. G.F.
(2000). Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure. Eur J Heart Fail
2: 107-112
[Abstract][Full Text]
Pullicino, P. M., Halperin, J. L., Thompson, J. L. P.
(2000). Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology
54: 288-288
[Abstract][Full Text]
Yeghiazarians, Y., Braunstein, J. B., Askari, A., Stone, P. H.
(2000). Unstable Angina Pectoris. NEJM
342: 101-114
[Full Text]
Cokkinos, D. V., Toutouzas, P. K.
(1999). Antithrombotic therapy in heart failure: a randomized comparison of warfarin vs. aspirin (HELAS). Eur J Heart Fail
1: 419-423
[Abstract][Full Text]
Anand, S. S., Yusuf, S.
(1999). Oral Anticoagulant Therapy in Patients With Coronary Artery Disease: A Meta-analysis. JAMA
282: 2058-2067
[Abstract][Full Text]
Kapral, M. K., Silver, F. L.
(1999). Preventive health care, 1999 update: 2. Echocardiography for the detection of a cardiac source of embolus in patients with stroke. CMAJ
161: 989-996
[Abstract][Full Text]
Gorter, J. W.
(1999). Major bleeding during anticoagulation after cerebral ischemia: Patterns and risk factors. Neurology
53: 1319-1319
[Abstract][Full Text]
Bossavy, J.-P., Sakariassen, K. S., Thalamas, C., Boneu, B., Cadroy, Y.
(1999). Antithrombotic Efficacy of the Vitamin K Antagonist Fluindione in a Human Ex Vivo Model of Arterial Thrombosis : Effect of Anticoagulation Level and Combination Therapy With Aspirin. Arterioscler. Thromb. Vasc. Bio.
19: 2269-2275
[Abstract][Full Text]
Freemantle, N., Cleland, J., Young, P., Mason, J., Harrison, J.
(1999). beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ
318: 1730-1737
[Abstract][Full Text]
Gorelick, P. B., Sacco, R. L., Smith, D. B., Alberts, M., Mustone-Alexander, L., Rader, D., Ross, J. L., Raps, E., Ozer, M. N., Brass, L. M., Malone, M. E., Goldberg, S., Booss, J., Hanley, D. F., Toole, J. F., Greengold, N. L., Rhew, D. C.
(1999). Prevention of a First Stroke: A Review of Guidelines and a Multidisciplinary Consensus Statement From the National Stroke Association. JAMA
281: 1112-1120
[Abstract][Full Text]
Anand, S. S., Yusuf, S., Pogue, J., Weitz, J. I., Flather, M.
(1998). Long-Term Oral Anticoagulant Therapy in Patients With Unstable Angina or Suspected Non–Q-Wave Myocardial Infarction : Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study Results. Circulation
98: 1064-1070
[Abstract][Full Text]
British Cardiac Society, , British Hyperlipidaemia Association, , British Hypertension Society, , endorsed by the British Diabetic Association,
(1998). Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart
80: 1S-29
[Full Text]
Altman, R.
(1998). Controversies in Antithrombotic Therapy in Cardiovascular Diseases. CLIN APPL THROMB HEMOST
4: 11-24
[Abstract]
Baker, W. F. JR
(1998). Thrombosis and Hemostasis in Cardiology: Review of Pathophysiology and Clinical Practice (Part I). CLIN APPL THROMB HEMOST
4: 51-75
[Abstract]
Jansson, J.-H., Boman, K., Brannstrom, M., Nilsson, T. K.
(1997). High Concentration of Thrombomodulin in Plasma Is Associated With Hemorrhage : A Prospective Study in Patients Receiving Long-term Anticoagulant Treatment. Circulation
96: 2938-2943
[Abstract][Full Text]
Miller, D. B.
(1997). Secondary Prevention for Ischemic Heart Disease: Relative Numbers Needed to Treat With Different Therapies. Arch Intern Med
157: 2045-2052
[Abstract]
Franco Gensini, G., Colella, A., Comeglio, M.
(1997). State-of-the-Art Review: Antiplatelet Agents and Thrombin Inhibitors: Combined Modality Therapy. CLIN APPL THROMB HEMOST
3: 82-85
Collins, R., Peto, R., Baigent, C., Sleight, P.
(1997). Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction. NEJM
336: 847-860
[Full Text]
Loh, E., Sutton, M. St. J., Wun, C.-C. C., Rouleau, J. L., Flaker, G. C., Gottlieb, S. S., Lamas, G. A., Moye, L. A., Goldhaber, S. Z., Pfeffer, M. A.
(1997). Ventricular Dysfunction and the Risk of Stroke after Myocardial Infarction. NEJM
336: 251-257
[Abstract][Full Text]
Julian, D G, Chamberlain, D A, Pocock, S J
(1996). A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. BMJ
313: 1429-1431
[Abstract][Full Text]
Albers, G. W., Yim, J. M., Belew, K. M., Bittar, N., Hattemer, C. R., Phillips, B. G., Kemp, S., Hall, E. A., Morton, D. J., Vlasses, P. H.
(1996). Status of Antithrombotic Therapy for Patients With Atrial Fibrillation in University Hospitals. Arch Intern Med
156: 2311-2316
[Abstract]
Smith, S. C. Jr
(1996). Risk-Reduction Therapy: The Challenge to Change : Presented at the 68th Scientific Sessions of the American Heart Association November 13, 1995 Anaheim, California. Circulation
93: 2205-2211
[Full Text]
McGovern, P. G., Pankow, J. S., Shahar, E., Doliszny, K. M., Folsom, A. R., Blackburn, H., Luepker, R. V., The Minnesota Heart Survey Investigators,
(1996). Recent Trends in Acute Coronary Heart Disease -- Mortality, Morbidity, Medical Care, and Risk Factors. NEJM
334: 884-890
[Abstract][Full Text]
Lacoste, L., Lam, J. Y.T., Hung, J., Letchacovski, G., Solymoss, C. B., Waters, D.
(1995). Hyperlipidemia and Coronary Disease : Correction of the Increased Thrombogenic Potential With Cholesterol Reduction. Circulation
92: 3172-3177
[Abstract][Full Text]
Hart, R. G., Boop, B. S., Anderson, D. C.
(1995). Oral Anticoagulants and Intracranial Hemorrhage : Facts and Hypotheses. Stroke
26: 1471-1477
[Abstract][Full Text]
Adachi, Y, Yokoyama, Y, Nanno, T, Yamamoto, T
(1995). Drug points: Potentiation of warfarin by interferon. BMJ
311: 292a-292
[Full Text]
Gorelick, P. B.
(1995). Stroke Prevention. Arch Neurol
52: 347-355
[Abstract]
van Bergen, P. F. M. M., Jonker, J. J. C., van Hout, B. A., van Domburg, R. T., Deckers, J. W., Azar, A. J., Hofman, A.
(1995). Costs and Effects of Long-term Oral Anticoagulant Treatment After Myocardial Infarction. JAMA
273: 925-928
[Abstract]
Cairns, J. A., Markham, B. A.
(1995). Economics and Efficacy in Choosing Oral Anticoagulants or Aspirin After Myocardial Infarction. JAMA
273: 965-967
[Abstract]
Barnett, H. J.M., Eliasziw, M., Meldrum, H. E.
(1995). Drugs and Surgery in the Prevention of Ischemic Stroke. NEJM
332: 238-248
[Full Text]
Flapan, A D
(1994). Fortnightly Review: Management of patients after their first myocardial infarction. BMJ
309: 1129-1134
[Full Text]
Berlakovich, G. A., Herbst, F., Mittlbock, M., Kretschmer, G.
(1994). The Choice of Material for Above-Knee Femoropopliteal Bypass: A 20-Year Experience. Arch Surg
129: 297-302
[Abstract]
Turpie, A., Gent, M., Laupacis, A., Latour, Y., Gunstensen, J., Basile, F., Klimek, M., Hirsh, J.
(1993). A Comparison of Aspirin with Placebo in Patients Treated with Warfarin after Heart-Valve Replacement. NEJM
329: 524-529
[Abstract][Full Text]
van der Meer, F. J. M., Rosendaal, F. R., Vandenbroucke, J. P., Briet, E.
(1993). Bleeding Complications in Oral Anticoagulant Therapy: An Analysis of Risk Factors. Arch Intern Med
153: 1557-1562
[Abstract]
Bauer, K. A.
(1993). Coumarin-Induced Skin Necrosis. Arch Dermatol
129: 766-768
[Abstract]
Ansell, J. E.
(1993). Oral Anticoagulant Therapy--50 Years Later. Arch Intern Med
153: 586-596
[Abstract]
Mennemeyer, S. T., Winkelman, J. W.
(1993). Searching for Inaccuracy in Clinical Laboratory Testing Using Medicare Data: Evidence for Prothrombin Time. JAMA
269: 1030-1033
[Abstract]
Cleophas, T. J. M., Tavenier, P., Niemeyer, M. G.
(1993). The Risk of Emergency Intestinal Bleeding Among Users of Acenocoumarin: A Population-Based Cohort Study. ANGIOLOGY
44: 85-92
[Abstract]
Kretschmer, G., Herbst, F., Prager, M., Sautner, T., Wenzl, E., Berlakovich, G. A., Zekert, F., Marosi, L., Schemper, M.
(1992). A Decade of Oral Anticoagulant Treatment to Maintain Autologous Vein Grafts for Femoropopliteal Atherosclerosis. Arch Surg
127: 1112-1115
[Abstract]
Landefeld, C. S., Anderson, P. A.
(1992). Guideline-based Consultation To Prevent Anticoagulant-related Bleeding: A Randomized, Controlled Trial in a Teaching Hospital. ANN INTERN MED
116: 829-837
[Abstract]
Smith, P., Arnesen, H., Abdelnoor, M.
(1992). Effects of Long-term Anticoagulant Therapy in Subgroups After Acute Myocardial Infarction. Arch Intern Med
152: 993-997
[Abstract]
McCurdy, S. A., White, R. H.
(1992). Accuracy and Precision of a Portable Anticoagulation Monitor in a Clinical Setting. Arch Intern Med
152: 589-592
[Abstract]
Bussey, H. I., Force, R. W., Bianco, T. M., Leonard, A. D.
(1992). Reliance on Prothrombin Time Ratios Causes Significant Errors in Anticoagulation Therapy. Arch Intern Med
152: 278-282
[Abstract]
Rothrock, J. F., Hart, R. G.
(1991). Antithrombotic Therapy in Cerebrovascular Disease. ANN INTERN MED
115: 885-895
[Abstract]
(1990). WARFARIN IMPROVES OUTCOMES AFTER MI. JWatch General
1990: 1-1
[Full Text]
Lichtman, J. H., Krumholz, H. M., Wang, Y., Radford, M. J., Brass, L. M.
(2002). Risk and Predictors of Stroke After Myocardial Infarction Among the Elderly: Results From the Cooperative Cardiovascular Project. Circulation
105: 1082-1087
[Abstract][Full Text]
Previous
